Log In
Sign Up
Romania
Citizenship:
Romania
Ph.D. degree award:
Mr.
Ioan
Tomuta
PhD
Professor
-
UNIVERSITATEA DE MEDICINA SI FARMACIE "IULIU HATIEGANU"
Researcher | Teaching staff | Scientific reviewer | Consultant | PhD supervisor
>20
years
Web of Science ResearcherID:
B-8433-2011
Personal public profile link.
Curriculum Vitae (27/03/2023)
Expertise & keywords
Drug design
Drug formulation
Drug release
Drug industry
Manufacturing
Projects
Publications & Patents
Entrepreneurship
Reviewer section
Quality by Design approach and development of Process Analytical Technology for a matrix type sustained–release product.
Call name:
Projects for Young Research Teams - RUTE -2014 call
PN-II-RU-TE-2014-4-1862
2015
-
2017
Role in this project:
Coordinating institution:
UNIVERSITATEA DE MEDICINA SI FARMACIE (U.M.F) Cluj-Napoca
Project partners:
UNIVERSITATEA DE MEDICINA SI FARMACIE (U.M.F) Cluj-Napoca (RO)
Affiliation:
UNIVERSITATEA DE MEDICINA SI FARMACIE (U.M.F) Cluj-Napoca (RO)
Project website:
https://qbdpatmatrixrs.wordpress.com/
Abstract:
The aim of the current proposal is to apply the Quality by Design (QbD) approach in development of the manufacturing technological process of matrix type sustained–release products and to use near infrared spectroscopy (NIRs) in association with chemometry as an adequate tool for Process Analytical Technology (PAT). The main factors affecting the release of drugs from hydrophilic matrix systems are related to drug characteristics (particle size, polymorphism), polymer (type, substituents of the side chain, particle size, intrinsic viscosity, percentage), formulation factors (other excipients, air trapped in the porosity, resistance to breakage) and technological factors (homogeneity of powder blend, compression force). Currently those factors are not monitored during the manufacturing process and variability affects product consistency (drug’s release profile/bioavailability) with consequences on quality of the final product. The project propose a scientific approach to overcome this difficulty by applying QbD order to define the Design Space in granulation, mixing and compression septs and development and validation NIRs methods for on-line monitoring of these steps. Therefore, the proposed project aims to find solutions for overcoming the problems of manufacturing high quality sustained release products by developing the innovative solution of applying enhanced process understanding via QbD in product development and NIRs as PAT tool for continuous process monitoring.
Read more
Development and preclinical evaluation of nanoparticulate drug delivery systems for targeted antitumor therapy of colorectal cancer
Call name:
Joint Applied Research Projects - PCCA-2011 call, Type 2
PN-II-PT-PCCA-2011-3.2-1060
2012
-
2016
Role in this project:
Key expert
Coordinating institution:
UNIVERSITATEA DE MEDICINA SI FARMACIE (U.M.F) Cluj-Napoca
Project partners:
UNIVERSITATEA DE MEDICINA SI FARMACIE (U.M.F) Cluj-Napoca (RO); UNIVERSITATEA BABES BOLYAI (RO); BIOTEHNOS SA (RO); UNIVERSITATEA DE STIINTE AGRICOLE SI MEDICINA VETERINARA CLUJ-NAPOCA (RO)
Affiliation:
UNIVERSITATEA DE MEDICINA SI FARMACIE (U.M.F) Cluj-Napoca (RO)
Project website:
https://pcca1060.wordpress.com/
Abstract:
The colorectal cancer remains a major health problem being the second cause of death by cancer in the world. Chemotherapy as major therapeutic approach for the treatment of cancer involves a high patient risk because of lack of tumor specificity of the cytotoxic drugs. Moreover the inefficiency and side effects of chemotherapy have been primarily associated with the formulation and biodistribution of the drug, toxicity to normal cells and the acquisition of drug resistance in the cancer cells. In order to overcome chemotherapy drawbacks, therapeutic bionanotechnologies based on the drug targeting concept might be a promise approach for cancer treatment.
Recent studies have shown the active involvement of inflammatory cells infiltrating the tumor, in tumor development by stimulating and supporting tumor angiogenesis. Tumor angiogenesis induced by the inflammatory pathways seems to be a central force in tumor growth and expansion. Inflammatory cell-targeting by using nanoparticulate delivery systems for certain drugs with primary or secondary anti-inflammatory effects in combination with nanoparticulate systems to deliver cytotoxic drugs to tumor cells might be a promise for the antitumor therapy.
Based on this approach, the aim of this proposal is to develop a successfull targeting strategy of two key cell players in tumor development, tumor and inflammatory cells. This aim will be accomplished by two main objectives: to develop suitable nanoparticulate drug delivery systems for selected drugs in the classes mentioned above and to assess their antitumor efficacy. The novelty of the proposal is to use a tumor targeting strategy for both processes vital for tumor progression, tumor cell proliferation and tumor-associated inflammation. Taking into account our premises, development of targeted antitumor nanosystems would have a significant impact on future anticancer therapy.
Read more
FILE DESCRIPTION
DOCUMENT
List of research grants as project coordinator or partner team leader
Significant R&D projects for enterprises, as project manager
R&D activities in enterprises
Peer-review activity for international programs/projects
[T: 0.2131, O: 137]